The CARDia trial protocol

Heart

Volumn 89, Issue 10, 2003, Pages 1125-1126

  Smith, David ^a  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DIABETES MELLITUS; HUMAN; METHODOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0141678897     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.10.1125     Document Type: Review

References (14)

1. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
2. Szabo Z, Hakanson E, Svedjeholm R, et al. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2002;74:712-9.
3. O'Neill W. Multivessel balloon angioplasty should be abandoned in diabetic patients. J Am Coll Cardiol 1998;31:20-2.
4. BARI Investigators. Influence of diabetes on 5 year mortality and morbidity in a randomised trial comparing CABG and PTCA inpatients with multivessel disease: the bypass angioplasty revascularisation investigation (BARI). Circulation 1997;96:1761-9.
5. RITA Trial Investigators. Coronary angioplasty versus coronary artery bypass surgery: the randomised intervention treatment of angina (RITA) trial. Lancet 1993;341:573-80.
6. King SB, III, Lembo NJ, Weintraub WS, et al. A randomised trial comparing coronary angioplasty with coronary artery bypass surgery. Emory angioplasty versus surgery trial (EAST). N Engl J Med 1994;331:1044-50.
7. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the arterial revascularisation therapy study (ARTS) trial. Circulation 2001;104:533-8.
8. Booth J, Stables RH, Clayton T, et al. Clinical outcome in diabetic patients with multi-vessel coronary artery disease treated with percutaneous coronary intervention compared to coronary bypass surgery: results from the stent or surgery (SoS) trial [abstract]. Heart (in press)
9. Brookes ST, Whitley E, Peters TJ, et al. Subgroup analyses in randomized controlled trial: quantifying the risks of false positives and false negatives. Health Technol Assess 2001;5(33):1-56.
10. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal proliferation after coronary stent implantation in patients with non insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-35.
11. Morice MC, Serruys PW, Sousa JE, et al. A randomised comparisaon of a sirolimus-eluting stent with a standard stent for coronary revascularisation. N Engl J Med 2002;346:1773-801.
12. Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinaemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki policemen study. Circulation 1998;98:398-404.
13. Aronson D. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 2002;59:297-301.
14. Morso SP, Ellis SG, Tuzcu M, et al. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularisation in diabetics. J Am Coll Cardiol 1999;33:1269-77.